1.Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin. 2019; 1: 7–34.
2.Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG Guidelines On Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017; 4: 618–629.
3.Huland H, Graefen M. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment? Eur Urol. 2015; 2: 175–178.
4.Fletcher SA, von Landenberg N, Cole AP et al. Contemporary National Trends in Prostate Cancer Risk Profile at Diagnosis. Prostate Cancer Prostatic Dis. 2019.
5.Mohler JL, Antonarakis ES, Armstrong AJ et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 5: 479–505.
6.Nagao K, Matsuyama H, Matsumoto H et al. Identification of Curable High-Risk Prostate Cancer Using Radical Prostatectomy Alone: Who are the Good Candidates for Undergoing Radical Prostatectomy Among Patients with High-Risk Prostate Cancer? Int J Clin Oncol. 2018; 4: 757–764.
7.Ploussard G, Masson-Lecomte A, Beauval JB et al. Radical Prostatectomy for High-Risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-Up in National Multicenter Study in 813 Patients and Assessment of Easy-To-Use Prognostic Substratification. Urology. 2011; 3: 607–613.
8.Cronin KA, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer-Am Cancer Soc. 2014; 3755–3757.
9.Cuccurullo V. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual (7Th Edition). European Journal of Nuclear Medicine & Molecular Imaging. 2011; 2: 408.
10.Weiss A, Chavez-Macgregor M, Lichtensztajn DY et al. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared with the Anatomic Stage in Breast Cancer. Jama Oncol. 2017; 2.
11.Camp RL, Marisa DF, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clin Cancer Res. 2004; 21: 7252–7259.
12.Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in Oncology: More than Meets the Eye. Lancet Oncol. 2015; 4: e173–180.
13.Shouval R, Labopin M, Gorin NC et al. Individualized Prediction of Leukemia-Free Survival After Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. Cancer-Am Cancer Soc. 2019.
14.Cho CSM, Gonen MP, Shia JM et al. A Novel Prognostic Nomogram is More Accurate than Conventional Staging Systems for Predicting Survival after Resection of Hepatocellular Carcinoma. J Am Coll Surgeons. 2008; 2: 281–291.
15.Wong SL, Kattan MW, McMasters KM, Coit DG. A Nomogram that Predicts the Presence of Sentinel Node Metastasis in Melanoma with Better Discrimination than the American Joint Committee On Cancer Staging System. Ann Surg Oncol. 2005; 4: 282–288.
16.Wu Y, Meyers JP, Shi G et al. A Nomogram for Predicting Survival and Retroperitoneal Lymph Node Dissection Treatment in Patients with Resected Testicular Germ Cell Tumors. J Surg Oncol. 2019; 3: 508–517.
17.Kim BH, Kim K, Chie EK et al. Risk Stratification and Prognostic Nomogram for Post-Recurrence Overall Survival in Patients with Recurrent Extrahepatic Cholangiocarcinoma. Hpb. 2017; 5: 421–428.
18.Kim Y, Park HC, Yoon SM et al. Prognostic Group Stratification and Nomogram for Predicting Overall Survival in Patients Who Received Radiotherapy for Abdominal Lymph Node Metastasis From Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 15–02). Oncotarget. 2017; 55: 94450–94461.
19.Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016; 2: 244–252.
20.Sundi D, Wang V, Pierorazio PM et al. Identification of Men with the Highest Risk of Early Disease Recurrence After Radical Prostatectomy. The Prostate. 2014; 6: 628–636.
21.Kim TH, Jeon HG, Jeong BC et al. Development of a New Nomogram to Predict Insignificant Prostate Cancer in Patients Undergoing Radical Prostatectomy. Scand J Urol. 2017; 1: 27–32.
22.Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of Cancer in the Biopsy Set Predicts Pathological Findings After Prostatectomy. J Urol. 2002; 5: 2032–2036.
23.Hamada R, Nakashima J, Ohori M et al. Preoperative Predictive Factors and Further Risk Stratification of Biochemical Recurrence in Clinically Localized High-Risk Prostate Cancer. Int J Clin Oncol. 2016; 3: 595–600.
24.Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-Risk Prostate Cancer: A Systematic Literature Review and Meta-Analysis. Eur Urol. 2013; 6: 1040–1048.
25.Sheng W, Zhang H, Lu Y. Survival Outcomes of Locally Advanced Prostate Cancer in Patients Aged ≪ 50 Years After Local Therapy in the Contemporary US Population. Int Urol Nephrol. 2018; 8: 1435–1444.
26.Danella JF, DeKernion JB, Smith RB, Steckel J. The Contemporary Incidence of Lymph Node Metastases in Prostate Cancer: Implications for Laparoscopic Lymph Node Dissection. J Urol. 1993; 6: 1488–1491.
27.Amin MB, Greene FL, Edge SB et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge From a Population-Based to a More “Personalized” Approach to Cancer Staging. CA Cancer J Clin. 2017; 2: 93–99.